Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Shed Non-Cancer R&D Costs, Allocate More Resources to Oncology: CEO
December 14, 2017
- Daiichi Sankyo, Puma Tie Up on HER2-Targeting Combo Therapy
December 14, 2017
- Mitsubishi Tanabe Hooks Up with 2 Japanese Startups on ALS
December 14, 2017
- Ono Links Up with Canada’s Cyclenium on Macrocycles
December 13, 2017
- Kaketsuken Announces Biz Transfer to Meiji-Kumamoto JV
December 13, 2017
- Atezolizumab-Avastin Combo Delivers Positive Data in 1st Line RCC: Chugai
December 12, 2017
- Empliciti Shows Positive Response in Newly Diagnosed Japanese Myeloma Patients: BMS
December 12, 2017
- Japan Drug Makers Driven by Overseas Sales, See Tepid Revenue at Home: Jiho Tally
December 12, 2017
- Halaven/Keytruda Combo Delivers ORR of 26.4% in Triple-Negative Breast Cancer: Interim Data
December 11, 2017
- AbbVie Hopes Maviret Will Encourage Potential Hep C Patients to Get Treatment: Hepatitis Biz Head
December 11, 2017
- Daiichi Sankyo to Consider Further Development of DS-8201 for HER2 Low-Expressing Breast Cancer
December 11, 2017
- Sanofi, Asahi Kasei Pharma Tie Up for Anti RA Treatment Kevzara
December 11, 2017
- Janssen Files Guselkumab for Palmoplantar Pustulosis in Japan
December 11, 2017
- Emicizumab Every Four Weeks Delivers Positive Data, Chugai Plans New Dosage Filing Next Year
December 8, 2017
- Avapro AGs Hit Market, Talion AG Won’t Arrive Until March
December 8, 2017
- FDA Clears Sunovion’s Nebulized COPD Drug
December 7, 2017
- Lenvima Filed for HCC in Taiwan: Eisai
December 7, 2017
- Astellas, Univ. of Tokyo, Chiba Univ. Strike Collaborative Research Deal on Rice-Based Oral Vaccine
December 7, 2017
- Positive Update Out for Burosumab in Adult XLH: Kyowa Kirin
December 6, 2017
- GSK Poised to Re-Enter Japan Oncology Space with Novel Myeloma Drug
December 6, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…